Jefferies Reports Favorable ACIP Stance For Dynavax Tech

According to Jefferies, Dynavax Technologies (NASDAQ: DVAX) is seeing a favorable ACIP stance for diabetes vaccination mandate.Jefferies said that, at the CDC's ACIP meeting, the hepatitis working group recommended a broad mandate to vaccinate all diabetics up to the age of 60 for hepatitis B (HBV). “We view this as a positive as it opens up a large market opportunity for DVAX's Heplisav HBV vaccine, and we see upside potential for even broader use in all diabetics. We expect Heplisav approval in early 2013.”Dynavax Technologies closed yesterday at $2.65.